EUVIMEDEUVIMED entdecken
Crossref

Chitosan-modified manganese oxide-conjugated methotrexate nanoparticles delivering 5-aminolevulinic acid as a dual-modal T1–T2* MRI contrast agent in U87MG cell detection

Yasin Ayyami, Marjan Ghorbani, Masoumeh Dastgir, Reza Malekzadeh, Tohid Mortezazadeh

Magnetic Resonance Materials in Physics, Biology and Medicine · 25.05.2024 · 37 (5) · 909-924

DOI: 10.1007/s10334-024-01169-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Magnetic Resonance Materials in Physics, Biology and Medicine, online erschienen am 25.05.2024. Verfasst von Yasin Ayyami und 4 weiteren Autor:innen. Beteiligte Einrichtung: Nutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Hauptthemen laut MEDLINE: Methotrexate, Contrast Media, Manganese Compounds, Magnetic Resonance Imaging. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Glioblastoma multiforme is a highly aggressive form of brain cancer, and early diagnosis plays a pivotal role in improving patient survival rates. In this regard, molecular magnetic resonance imaging has emerged as a promising imaging modality due to its exceptional sensitivity to minute tissue changes and the ability to penetrate deep into the brain. This study aimed to assess the efficacy of a novel contrast agent in detecting gliomas during MRI scans. MATERIALS AND METHODS: The contrast agent utilized modified chitosan coating on manganese oxide nanoparticles. The modification included adding methotrexate and 5-aminolevulinic acid (MnO2/CS@5-ALA-MTX) to target cells with overexpressed folate receptors and breaking down excess hydrogen peroxide in tumor tissue, resulting in enhanced signal intensity in T1-weighted MR images but diminished signal intensity in T2*-weighted MR images. RESULTS: The nanosystem was characterized and evaluated in MR imaging, safety, and ability to target cells both in vivo and in vitro. MTX-free nanoparticles (MnO2/CS@5-ALA NPs) had no obvious cytotoxicity on cell lines U87MG and NIH3T3 after 24/48 h at a concentration of up to 160 µgr/mL (cell viability more than 80%). In this system, methotrexate enables tumor targeting and the MnO2/5-ALA improves T1-T2*-weighted MRI. In addition, MRI scans of mice with M109 carcinoma indicated significant tumor uptake and NP capacity to improve the positive contrast effect. CONCLUSION: This developed MnO2/CS@5-ALA-MTX nanoparticle system may exhibit great potential in the accurate diagnosis of folate receptor over-expressing cancers such as glioblastoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateContrast MediaManganese CompoundsMagnetic Resonance ImagingChitosanOxidesAminolevulinic AcidNanoparticlesGlioblastomaCell SurvivalHumansAnimalsMiceCell Line, TumorBrain NeoplasmsNIH 3T3 Cells

Stichwörter der Autor:innen

Cancer targetingDrug deliveryGlioblastoma multiformeMRI contrast agentManganese oxide (MnO2) nanoparticles

Substanzen

MethotrexateContrast MediaManganese CompoundsChitosanmanganese oxideOxidesAminolevulinic Acid

Autor:innen und Institutionen

  • Nutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Department of Medical Physics, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Iran Polymer and Petrochemical Institute, P.O.Box: 14965/115, Tehran, Iran.
  • Department of Medical Physics, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. reza.malek78@yahoo.com.
  • Nutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. tmortezazadeh@gmail.com.
  • Department of Medical Physics, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. tmortezazadeh@gmail.com.

Zitieren

APA

Ayyami, Y., Ghorbani, M., Dastgir, M., Malekzadeh, R., & Mortezazadeh, T. (2024). Chitosan-modified manganese oxide-conjugated methotrexate nanoparticles delivering 5-aminolevulinic acid as a dual-modal T1–T2* MRI contrast agent in U87MG cell detection. Magnetic Resonance Materials in Physics, Biology and Medicine, 37(5), 909-924. https://doi.org/10.1007/s10334-024-01169-4

Vancouver

Ayyami Y, Ghorbani M, Dastgir M, Malekzadeh R, Mortezazadeh T. Chitosan-modified manganese oxide-conjugated methotrexate nanoparticles delivering 5-aminolevulinic acid as a dual-modal T1–T2* MRI contrast agent in U87MG cell detection. Magnetic Resonance Materials in Physics, Biology and Medicine. 2024;37(5):909-924. doi:10.1007/s10334-024-01169-4

BibTeX
@article{Ayyami2024,
  author = {Ayyami, Yasin and Ghorbani, Marjan and Dastgir, Masoumeh and Malekzadeh, Reza and Mortezazadeh, Tohid},
  title = {Chitosan-modified manganese oxide-conjugated methotrexate nanoparticles delivering 5-aminolevulinic acid as a dual-modal T1–T2* MRI contrast agent in U87MG cell detection},
  journal = {Magnetic Resonance Materials in Physics, Biology and Medicine},
  year = {2024},
  volume = {37},
  number = {5},
  pages = {909--924},
  doi = {10.1007/s10334-024-01169-4}
}
Kostenlos starten →